Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buprenorphine augmentation for psychosis in bipolar I disorder with opioid abuse
IRCT2016040527236N1Phase 2Completed
- Sponsor
- Kerman University of Medical Sciences
- Start
- Sep 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of buprenorphine in bipolar I disorder, Schizophrenia Spectrum Disorders (SSD) and opioid use disorder (OUD), sponsored by Kerman University of Medical Sciences. Started Sep 2016; status: completed.
02
Drugs
buprenorphine
03
Conditions
bipolar I disorderSchizophrenia Spectrum Disorders (SSD)opioid use disorder (OUD)
Beyond the preview
Go deeper on IRCT2016040527236N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT2016040527236N1.